MétaCan
Menu
Back to cohort
Record W2948216318 · doi:10.1186/s12933-019-0864-7

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

2019· review· en· W2948216318 on OpenAlexaff
Jean‐Charles Fruchart, Raúl D. Santos, Carlos A. Aguilar‐Salinas, Masanori Aikawa, Khalid Al‐Rasadi, Pierre Amarenco, Philip J. Barter, R Češka, Alberto Corsini, Jean‐Pierre Després, Patrick Duriez, Robert H. Eckel, М. В. Ежов, Michel Farnier, Henry N. Ginsberg, Michel P. Hermans, Shun Ishibashi, Fredrik Karpe, Tatsuhiko Kodama, Wolfgang Köenig, Michel Krempf, Soo Lim, Alberto Lorenzatti, Ruth McPherson, Jesús Millán Núñez-Cortés, Børge G. Nordestgaard, Hisao Ogawa, Chris J. Packard, Jorge Plutzky, Carlos I. Ponte‐Negretti, Aruna D. Pradhan, Kausik K. Ray, Željko Reiner, Paul M. Ridker, Massimiliano Ruscica, Shaukat Sadikot, Hitoshi Shimano, Piyamitr Sritara, Jane K. Stock, Ta‐Chen Su, Andrey V. Susekov, André Tartar, Marja‐Riitta Taskinen, Alexander Tenenbaum, Lâle Tokgözoğlu, Brian Tomlinson, Anne Tybjærg‐Hansen, P. Valensi, Michal Vrablı́k, Walter Wahli, Gerald F. Watts, Shizuya Yamashita, Koutaro Yokote, Alberto Zambon, Peter Libby

Bibliographic record

VenueCardiovascular Diabetology · 2019
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicPeroxisome Proliferator-Activated Receptors
Canadian institutionsWilfrid Laurier UniversityCanadian Heart Research CentreUniversity of OttawaUniversité Laval
FundersServierOtsuka PharmaceuticalShionogiAstellas PharmaIonis PharmaceuticalsMylanAmarin CorporationDaiichi Sankyo EuropeKowa CompanySanofiRegeneron PharmaceuticalsDaiichi-SankyoTeva Pharmaceutical IndustriesAstraZenecaPfizerAmgen
KeywordsDyslipidemiaMedicinePeroxisome proliferator-activated receptor alphaDiabetes mellitusPeroxisome proliferator-activated receptorInternal medicineAgonistType 2 Diabetes MellitusType 2 diabetesPPAR agonistBioinformaticsEndocrinologyPharmacologyReceptorNuclear receptorBiologyBiochemistryTranscription factor

Abstract

fetched live from OpenAlex

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.001
Scholarly communication0.0010.002
Open science0.0010.001
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.274
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations143
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueCardiovascular DiabetologySame topicPeroxisome Proliferator-Activated ReceptorsFrench-language works237,207